The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children 2-11 years ...

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...

Here is how Bavarian Nordic (BVNRY) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

The U.S. Food and Drug Administration has also approved Bavarian's shot, but only for use in adults 18 years and older, although it granted Emergency Use Authorization for its use in adolescents ...

Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety between teenagers and adults in an NIH study.

COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s announced mpox vaccine order and additional orders secured, ...

The MVA-BN vaccine, licensed in the United States to prevent smallpox and mpox, is well tolerated and seems effective in adolescents.

Is Bavarian Nordic (BVNRY) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. Bavarian Nordic is a member of our Medical group ...

One stock to keep an eye on is Bavarian Nordic (BVNRY). BVNRY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. Another notable valuation metric for BVNRY is its P/B ...